Citations

Clear

1526 citation(s) found for "Sun, D".

SUN-292 Examining Predictive Elements Influencing Metastasis to Right Para Esophageal Lymph Nodes in Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis
Haider, Rabbia , Khawar, Muneeb , Abid, Muhammad Hanan, Khawar, Mirza Muhammad Hadeed , Shaukat, Muneeba, Cheema, M S, Komel, Aqsa, Khan, Muhammad Huzaifa Ahmed, Noureen, Rimsha, Batool, Arshia , Qadeer, Abdul, Ullah, Aman, Abid, Muhammad Hanan, Shaukat, Muneeba, Cheema, Muhammad Bilal Asad, Mubashir, Mohammad Maheer, Kirchoff, Robert W.

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.2494 Get It

Abstract Disclosure: A. Ullah: None. R. Haider: None. M. Khawar: None. M. Abid: None. M. Hadeed Khawar: None. M. Shaukat: None. M. Asad Cheema: None. A. Komel: None. M. Ahmed Khan: None. R. Noureen: None. A. Batool: None. M. Mubashir: None. A. Qadeer: None. R. W. Kirchoff: None. Background: The role of dissecting the right paraesophageal lymph node (RPELN) in managing papillary thyroid carcinoma (PTC) remains a subject of debate. This meta-analysis examines both established and novel risk factors associated with RPELN metastasis. Methods: Relevant studies published up to December 2024 were retrieved using PubMed, Embase, Ovid, and Scopus search engines. Data were extracted and evaluated using the Newcastle-Ottawa scale. Statistical analysis was performed using Review Manager 5.4, with heterogeneity assessed through the Q-test and I²-test. Sensitivity analysis was conducted using the leave-one-out method, and the Egger regression test was used to generate a funnel plot for publication bias assessment. Results: Out of 2,444 articles screened, 26 studies involving 16,427 patients were included in the meta-analysis. The overall RPELN metastasis rate was 12.98% (2,133/16,427). The pooled analysis revealed significant associations between RPELN metastasis and the following factors: age under 55 years (P < 0.00001), male gender (P < 0.00001), tumor size >1 cm (P < 0.00001), multifocality (P < 0.00001), capsular invasion (P < 0.00001), vascular invasion (P < 0.00001), extra-thyroidal extension (P < 0.0001), central lymph node metastasis (P < 0.00001), lateral lymph node metastasis (P < 0.00001), Hashimoto’s thyroiditis (P = 0.002), micro-calcifications (P = 0.01), and altered echogenicity (P = 0.03). Conversely, no significant associations were observed for tumor location in the right lobe (P = 0.07), superior pole (P = 0.08), middle pole (P = 1.00), inferior pole (P = 0.28), or tumor margins (P = 0.93) (all P > 0.05). Conclusion: Factors such as age <55, male sex, tumor size >1 cm, multifocality, capsular invasion, vascular invasion, extra-thyroidal extension, central lymph node metastasis, lateral lymph node metastasis, and Hashimoto’s thyroiditis are significantly associated with RPELN metastasis. These should be carefully considered during RPELN dissection in PTC management. Presentation: Sunday, July 13, 2025
SUN-612 Gender-Specific Prevalence and Incidence Trends in Type 1 Diabetes Mellitus: A Global Burden of Disease Analysis in Adolescents and Young Adults (Aged 15-39) from 1990 to 2021
Kakakhel, Mian Zahid Jan , Fatima, Sumaiyah, Ahmad, Husnain , Ibrahim, Arwa , Haider, Rabbia, Jawad, Hamna , Qadeer, Abdul , Khawar, Muneeb , Ahmed, Faizan , Fatima, Sumaiyah, Rahman, Waqas, Ikram, Jibran , Kirchoff, Robert W.

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.1261 Get It

Abstract Disclosure: M. Kakakhel: None. S. Fatima: None. H. Ahmad: None. A. Ibrahim: None. W. Rahman: None. R. Haider: None. H. Jawad: None. A. Qadeer: None. M. Khawar: None. F. Ahmed: None. J. Ikram: None. R. Kirchoff: None. Background: Across the world, type 1 diabetes mellitus (T1DM) is a major health problem for teenagers and young people. This study aims to examine the incidence and prevalence of T1DM by gender in the 15-39 age range between 1990 and 2021. Methods: We analyzed data from the Global Burden of Disease (GBD) to evaluate incidence and prevalence rates of T1DM in each gender from 1990 to 2021. The Annual Percentage Change (APC) and The Annual Average Percentage Change (AAPC) was used to assess trends, with p-values determining the statistical significance. Results: From 1990 to 2021, the global prevalence of T1DM was found to be increased steadily for both genders, with the highest rates recorded in 2021: 247.32 per 100,000 for females and 246.47 per 100,000 for males. Incidence rates in 2021 showed a contrasting pattern, with males exhibiting higher rates (7.18 per 100,000) compared to females (5.98 per 100,000). AAPC analysis showed that males exhibit a faster rise in both prevalence and incidence compared to females over the study period. The difference in AAPC between males and females is more pronounced for prevalence (+0.3748%) compared to incidence (+0.1956%), with all AAPC values being statistically significant (p < 0.000001). Following the APC analysis, other significant trends were revealed. Male incidence experienced the greatest increase during 2015-2021, with an APC of +1.9033% (p < 0.000001), whereas female incidence increased most between 2011 and 2014 (APC = +1.3050%; p < 0.000001). In contrast, the most significant decline in incidence was observed in females during 1990-1992, with an APC of +0.1665% (p = 0.006799), which was the lowest increase in the dataset. For prevalence, males exhibited the highest increase during 2015-2021, with an APC of +1.3938% (p < 0.000001), whereas females had their peak increase during 2006-2009, with an APC of +0.8957% (p < 0.000001). The slowest increase in prevalence for females occurred during 2014-2019, with an APC of +0.4591% (p < 0.000001). Conclusion: The prevalence and incidence of T1DM among people aged 15-39 increased significantly between 1990 and 2021, with a greater increase in males. This highlights the need for gender-specific strategies in T1DM prevention and management, and research into the factors driving these disparities. Presentation: Sunday, July 13, 2025
SUN-613 Regional Disparities in Mortality and Disability-Adjusted Life Years (DALYs) Due to Type 1 Diabetes in Adolescents and Young Adults From 1990 to 2021: A Global Burden of Disease Study
Kakakhel, Mian Zahid Jan , Fatima, Sumaiyah, Ahmad, Husnain , Khan, M. Adil , Rai, Anushree , Qadeer, Abdul , Haider, Rabbia, Khawar, Muneeb , Habib, Usama, Jawad, Hamna , Ikram, Jibran, Fatima, Sumaiyah, Ahmed, Faizan , Kirchoff, Robert W.

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.1262 Get It

Abstract Disclosure: M. Kakakhel: None. S. Fatima: None. H. Ahmad: None. M. Khan: None. A. Rai: None. A. Qadeer: None. R. Haider: None. M. Khawar: None. U. Habib: None. H. Jawad: None. J. Ikram: None. F. Ahmed: None. R. Kirchoff: None. Introduction: Type 1 Diabetes Mellitus (T1DM) is a disease that affects people all over the world. This condition causes significant morbidity, as measured by Disability-Adjusted Life Years (DALYs) and mortality rates, and its severity varies worldwide. The purpose of this study is to examine trends in T1DM-related death rates and DALYs across 26 geographical areas from 1990 to 2021 in order to provide a current picture of the disease's consequences and identify regional differences. Methods: This study examined DALYs and mortality rates per 100,000 people in individuals aged 15-39 years using data from the Global Burden of Disease Study from 1990 to 2021. Trends were assessed using the Average Annual Percentage Change (AAPC), with p-values used to define statistical significance. The study examined 26 regions with varied socioeconomic development indices (SDI). Using confidence intervals to account for data uncertainty, DALYs and mortality were examined to investigate the disease burden across time. Results: In 1990, the Middle SDI region had the highest DALYs at 298,352 (95% CI: 256,144 -349,670), which reached 382,857 (95% CI: 213,704-317,664) by 2021 (AAPC = 0.15, P-value < 0.000001). The region with the highest DALYs in 2021 was the Low-Middle SDI, with 419,772 (95% CI: 344,307- 495,496) cases (AAPC = -2.93, P-value = <0.000001). From 1990 to 2021, Oceania consistently had the lowest DALYs of 1,895 (95% CI: 1,264-2,577) and 4,210(95% CI: 3,011-5,724), respectively (AAPC= 0.15, P-value = 0.0004). Mortality rates in 1990 were highest in the Middle SDI area with 3,758 deaths (95% CI: 3,343-4,332) (AAPC= -1.23, P-value = <0.000001), but by 2021, South Asia had the highest mortality rate at 5,189(95% CI: 4,272-6,087) (AAPC= -0.49). Oceania had the lowest mortality rate of 25 deaths (95% CI 145-35) (AAPC = 0.193, P-value = <0.0004) in 1990, whereas Australasia had the lowest mortality rate of 28 deaths (95% CI 26-29) in 2021 (AAPC = -0.93, P-value = <0.000001). Conclusion: From 1990 to 2021, the global burden of type 1 diabetes—as indicated by DALYs and death rates—underwent a substantial shift, with significant rises in several regions. DALYs were highest in the Middle SDI region in 1990 but have migrated to the Low-Middle SDI region by 2021, reflecting shifting healthcare issues and demographics. Mortality rates followed a similar pattern, with South Asia and the Low-Middle SDI regions experiencing the highest rates in 2021. Over both time periods, however, Oceania and Australasia consistently had the lowest DALYs and death rates. These findings emphasise the critical need for targeted interventions in high-burden areas. Addressing these differences is crucial for decreasing the global burden of T1DM. Presentation: Sunday, July 13, 2025
SUN-614 Sex-Stratified Mortality and Disability-adjusted Life Years due to Type 1 Diabetes in Adolescents and Young Adults from 1990 to 2021: A Global Burden of Disease Study
Ahmad, Husnain , Fatima, Sumaiyah, Kakakhel, Mian Zahid Jan , Khan, Iqra , Raza, Ahmed , Haider, Rabbia, Khawar, Muneeb , Jawad, Hamna , Ikram, Jibran, Ahmed, Faizan , Fatima, Sumaiyah, Khan, Zarak, Qadeer, Abdul, Ullah, Fazal, Kirchoff, Robert W.

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.1263 Get It

Abstract Disclosure: H. Ahmad: None. S. Fatima: None. M. Kakakhel: None. I. khan: None. A. Raza: None. Z. Khan: None. R. Haider: None. A. Qadeer: None. M. Khawar: None. F. Ullah: None. H. Jawad: None. J. Ikram: None. F. Ahmed: None. R.W. Kirchoff: None. Background: Type 1 diabetes mellitus (T1DM) is an autoimmune condition, characterized by the destruction of pancreatic beta cells, resulting in lifelong dependency on insulin. It is a significant health burden in adolescents and young adults, with long-term complications affecting quality of life and survival. We aim to explore sex-stratified trends in mortality and disability-adjusted life years (DALYs) due to T1DM from 1990 to 2021. Methods: We obtained sex-stratified data for adolescents and young adults (15-39 years) with T1DM from the Global Burden of Disease (GBD) from 1990 to 2021. The mortality rates were age-standardized and expressed per 100,000 deaths. Trends were analyzed as annual percentage change (APC) and average APC (AAPC) using Joinpoint Regression. Results: From 1990 to 2021, deaths due to T1DM in adolescent and young adult males increased globally from 7,123 to 9,244 per annum, with age-standardized mortality rates (ASMRs) decreasing from 0.64 to 0.61 and standardized DALYs rising from 49.56 to 51. In females, deaths rose from 6,160 to 6,892, with ASMRs declining from 0.57 to 0.47 and DALYs declining from 47.12 to 43.11. Despite the apparent rise in deaths, ASMRs exhibited a significant decline in both sexes, with an AAPC of -0.16% (95% CI: -0.20 to -0.12) in males and -0.62% (-0.68 to -0.55) in females, four times that of in males. The DALYs showed a significant decline in females with an AAPC of -0.31% (-0.35 to -0.26) but a significant increase in males with an AAPC of 0.09% (0.04 to 0.12). Males showed the greatest APC increase in ASMRs of 1.34% from 1990 to 1994, while females showed the greatest APC increase of 0.45% from 1990 to 2000, three times less and over twice the period seen in males. This was followed by the greatest APC decline of -1.14% in females from 2001 to 2011, and a non-significant decline of -0.14% till 2021. Males experienced the greatest decline of -1.14% from 2000 to 2013. It then increased significantly from 2013 to 2018 (APC: 0.73%), followed by a significant decline of -0.62% till 2021, almost four times that in females. DALYs showed a similar trend in females with the greatest increase of 0.45% from 1990 to 2000, followed by the greatest decrease of -1.14% till 2011, and then a non-significant decline of -0.14 till 2021. Males showed the greatest increase of 1.24% from 1990 to 1994 and the greatest decrease of 0.63% from 2000 to 2013, followed by a much smaller decline. Conclusion: Although ASMRs declined, the recent decline in ASMRs in females is becoming less pronounced highlighting the importance of ongoing monitoring and improvement strategies. The disparity in DALYs between males and females also demands the need for targeted interventions addressing male-specific challenges to reduce the burden of T1DM. Presentation: Sunday, July 13, 2025
SUN-037 Operative Ethanol Ablation as a Treatment for Pediatric Pancreatic Neuroendocrine Tumors
Mouallem, Rayane El, McKenzie, Travis J. , Lteif, Aida

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.1626 Get It

Abstract Disclosure: R. El Mouallem: None. T. McKenzie: None. A.N. Lteif: None. Background- Pancreatic neuroendocrine tumors (PNETs) are rare, but their incidence is rising. Ethanol ablation is increasingly used in adult patients with insulinomas or small nonfunctional PNETs, particularly in patients who are ineligible for surgical resection. Ethanol ablation of a PNET has not been previously reported in the pediatric population. Clinical Case- A 12-year-old female with known multiple endocrine neoplasia type 1 (MEN1) and multifocal PNETs presented for evaluation of a 1.3 cm nonfunctional, Dotatate avid pancreatic uncinate lesion. A CT angiogram of the pancreas revealed an arterially enhancing 1.3 cm nodule, which measured 8 mm one year prior. There was no evidence of metastatic disease. Given the increasing size of the lesion and young age of the patient, operative intervention was pursued. Due to the depth of the lesion and its proximity to the pancreatic duct during operative pancreas ultrasonography, surgical enucleation was deemed non-feasible. During the procedure, 7 additional subcentimeter pancreatic lesions concerning for PNETs were identified in the pancreatic body, tail, head and neck-body junction. Ultrasound guided ethanol ablation of the primary lesion was performed. Follow-up imaging demonstrated a promising response. 7 months post ablation, a Dotatate PET CT scan showed persistent focal uptake in the region of the ablated nodule. However, by 9 months, MRI abdomen revealed a decrease in the size of the lesion, now measuring 6 mm, with stable Dotatate uptake. By 19 months post ethanol ablation, the previously hyper-enhancing lesion was no longer visible on MRI, demonstrating complete structural resolution. Conclusion- This case demonstrates that ethanol ablation is a promising treatment option for PNETs in the pediatric population. Given the complexities of surgical resection in children, particularly for deep or anatomically challenging lesions, ethanol ablation offers a potentially less morbid alternative with encouraging outcomes. Further research may establish this approach as a viable option for select pediatric patients. Presentation: Sunday, July 13, 2025
SUN-061 Recovery of Adrenal Insufficiency After Surgical Remission of Endogenous Hypercortisolism: A Prospective Cohort Study
Chacko, Shireen R , Sharma, Shubhangi Sharma , Ahmadian, Sarina , Achenbach, Sara J., Atkinson, Elizabeth J. , Fell, Vanessa , Saini, Jasmine , Gompel, Jamie J. Van , Young, William F. , Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.1646 Get It

Abstract Disclosure: S.R. Chacko: None. J. Saini: None. S. Sharma Sharma: None. S. Ahmadian: None. S.J. Achenbach: None. E. Atkinson: None. V. Fell: None. J.J. Van Gompel: None. W.F. Young, Jr.: None. I. Bancos: None. Context: Evidence on the duration of postoperative adrenal insufficiency (AI) in patients with endogenous hypercortisolism is scarce. Objective: To determine the duration of postoperative AI and to identify factors associated with the duration of AI in patients undergoing surgery for endogenous hypercortisolism.Methods: We conducted a single center prospective cohort study, 2019-2024, of patients with endogenous hypercortisolism [Cushing syndrome (CS) or mild autonomous cortisol secretion (MACS)] treated with surgery. Associations of demographics, BMI, clinical and biochemical hypercortisolism severity, subtype of hypercortisolism, presurgical hypercortisolism duration and glucocorticoid type in relation to duration of AI were investigated. Results: The 110 patients [36% MACS, 46% pituitary CS, 15% adrenal CS, 3% ectopic CS, median age 50 years (IQR: 40-60), 82% women] who developed postsurgical AI were followed for a median duration of 26 months (IQR: 15-38). By the end of follow up, 96 patients (87%) had recovery of AI. The median time to recovery of AI was shorter in MACS vs. Overt Cushing syndrome (3.0 months (95% CI: 2.5-6.2) vs. 12.3 months (95% CI 9.0-17.3), P =0.002). Biochemical severity score (r=0.32, P=0.002) and duration of preoperative hypercortisolism symptoms (r=0.29, P=0.005), but not age, sex, BMI, clinical severity, or glucocorticoid type were associated with the duration of AI. We found no differences in the duration of AI between patients with ACTH-dependent vs ACTH-independent CS (12.3 months (95% CI: 6.0-17.2) vs 13.9 months (95% CI: 9.0-25.5), P =0.7).Conclusion: In this interim analysis, we showed that after surgical remission of endogenous hypercortisolism, duration of postoperative AI was longer in CS compared to MACS. Additionally, higher biochemical hypercortisolism severity score and a longer duration of symptoms suggestive of hypercortisolism were associated with a longer duration of postoperative AI. Presentation: Sunday, July 13, 2025
SUN-655 Weight Loss with Topiramate and Phentermine Combination Therapy in a Patient with Bardet-Biedl Syndrome (BBS)
Hassan, Doha , Kumar, Seema , Muthusamy, Kalpana , Salama, Mostafa

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.165 Get It

Abstract Disclosure: D. Hassan: None. M. Salama: None. S. Kumar: None. K. Muthusamy: None. Background: Obesity is prevalent among individuals with Bardet-Biedl Syndrome (BBS), affecting approximately 72%-86% of patients. Setmelanotide, an MC4R agonist, is approved for the treatment of obesity in patients with BBS. It reduces hyperphagia and improves quality of life. However, the high cost of setmelanotide and the need for daily injections limit its use. Affordable and effective alternative pharmacotherapies are needed for managing obesity in patients with BBS. Here, we present a case of an adult with BBS who experienced significant weight loss following treatment with a combination of topiramate and phentermine. Clinical Case: A 29-year-old Hispanic female with BBS due to a homozygous BBS2 mutation (NM_031885.3, c.717+1G>T, GT donor) was evaluated for migraine. BMI was elevated at 42.5 kg/m², and obesity was complicated by obstructive sleep apnea, chronic respiratory failure requiring supplemental oxygen with activity, impaired fasting glucose (101 mg/dL; reference range [RR]: 70-100 mg/dL), and dyslipidemia (triglycerides: 252 mg/dL [RR: 30-150 mg/dL]; very low-density lipoprotein (VLDL): 50.4 mg/dL [RR: 8-30 mg/dL]; total cholesterol: 190 mg/dL [RR: 0-200 mg/dL]; high-density lipoprotein (HDL): 40 mg/dL [RR: 40-60 mg/dL]). She had polydactyly, retinal dystrophy, developmental delay and subclinical hypothyroidism. Topiramate was initiated at 25 mg and subsequently increased to 50 mg. At 31 years of age, BMI was 40.5 kg/m², and weight had decreased by 7.5 kg after two years of therapy with topiramate and lifestyle interventions. Phentermine 30 mg daily was added. She experienced a notable appetite-suppressing effect, reduced nighttime eating, fewer sugar cravings, and decreased stress-related eating. She was able to extend the duration of exercise with improved endurance. She reported constipation as a side effect but had no other intolerances. After three months of phentermine therapy, BMI decreased to 34.96 kg/m². Repeat metabolic profile revealed fasting glucose 70 mg/dL, HbA1c 5.5% (RR: 4.5-5.6%), triglycerides 204 mg/dL, VLDL 40.8 mg/dL, total cholesterol 175 mg/dL, HDL 38 mg/dL, and low-density lipoprotein (LDL) 96 mg/dL (RR: 70-100 mg/dL). Eight months after starting phentermine, BMI further decreased to 32.31 kg/m², reflecting a 25% total weight loss. Conclusion: This case report highlights the excellent weight loss response (25% total weight loss) and significant improvement in metabolic profile with phentermine and topiramate combination therapy in a patient with BBS. The effects of this combination therapy have not been formally studied in BBS, emphasizing the need for further research to evaluate the efficacy of conventional anti-obesity medications—used alone, sequentially, or in combination with setmelanotide—to optimize weight and metabolic outcomes. Keywords: Bardet-Biedl Syndrome, obesity, topiramate, phentermine, weight loss. Presentation: Sunday, July 13, 2025
SUN-653 Impact of GLP-1 Agonist on Outcomes in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Systematic Review and Meta-Analysis
Ahmed, Ashraf, Kaddoura, Rasha, Almas, Talal, Anavekar, Nandan, Ahmed, Ashraf, Kaddoura, Rasha, Almas, Talal, Anavekar, Nandan

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.163 Get It

Abstract Disclosure: A. Ahmed: None. R. Kaddoura: None. T. Almas: None. N. Anavekar: None. Background: There is a recent interest focused on the use of glucagon-like peptide 1 (GLP-1) agonists, which are primarily used for diabetes and weight management, as a potential therapeutic approach for heart failure with persevered ejection fraction (HFpEF). We aim to evaluate the effects of GLP-1 agonists versus placebo on hospitalization rates, functional capacity, and cardiometabolic parameters in patients with HFpEF and obesity. Methods: We performed a systematic review and meta-analysis according to Cochrane handbook for systematic reviews and the preferred reporting items for systematic reviews and meta-analysis. We systematically reviewed three databases: PubMed, Embase, and Scopus, from inception to June 23rd, 2024, to investigate the comparative outcomes between GLP-1 agonist and placebo. Results: We identified 453 articles that were screened at the title and abstract level. We retrieved 14 citations and reviewed them in detail, among which two articles were eligible to be pooled. Hospitalization rates for heart failure were significantly reduced by 71 % (OR 0. 29 95 % CI: 0. 14-0. 58 p=0. 0005 I²=0 %), with GLP-1 agonist indicating a significant impact on lowering the cost of hospital admissions. Furthermore, GLP1 agonists significantly decreased body weight (MD -5. 64 kg 95 % CI: -11. 03 to -0. 25 p=0. 0404 I²=99 and waist circumference (MD -7. 09 cm 95 % CI: -8. 05 to -6. 14 p0. 0001 I²=76 %) demonstrating the positive effects of GLP-1 agonists on body composition. Improvements in functional capacity were evidenced by an increase in the 6-MWD (MD 15.10 m, 95% CI: 14.87-15.34, p<0.0001; I²=0%) (Fig 1 panel D). However, changes in systolic blood pressure were not statistically significant (MD -1.30 mmHg, 95% CI: -4.13 to 1.52, p=0.3660; I²=90%). Conclusion: GLP-1 agonists significantly reduce hospitalization rates and improve weight management and functional capacity in patients with HFpEF. However, further studies are warranted to consolidate these findings, explore the long-term cardiovascular outcomes, and address the cost-effectiveness of GLP-1 agonists. Presentation: Sunday, July 13, 2025
SUN-416 Crinecerfont Improves Clinical Outcomes in Adults With Classic Congenital Adrenal Hyperplasia: 1-Year Results From the CAHtalyst™ Adult Study
Auchus, Richard J, Hamidi, Oksana, Bancos, Irina, Saag, Kenneth, Falhammar, Henrik, Srirangalingam, Umasuthan, Calanchini, Matilde, Jen, Eric, Lin, Vivian H, Sturgeon, Julia, Chan, Jean L, Auchus, Richard J, Hamidi, Oksana, Bancos, Irina, Saag, Kenneth, Falhammar, Henrik, Srirangalingam, Umasuthan, Calanchini, Matilde, Jen, Eric, Lin, Vivian H, Sturgeon, Julia, Chan, Jean L

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.386 Get It

Abstract Disclosure: R.J. Auchus: Has been involved in contracted research with companies such as Neurocrine Biosciences/Neurocrine UK, LTD, Spruce Biosciences, Corcept Therapeutics, Crinetics Pharmaceuticals, Recordati Rare Diseases, Adrenas Therapeutics, and Mineralys Pharmaceuticals, Served as consultant for organizations like Quest Diagnostics, Corcept Therapeutics, Xeris Pharmaceuticals, Crinetics Pharmaceuticals, Novo Nordisk, Neurocrine Biosciences/Neurocrine UK, LTD, Recordati Rare Diseases, H Lundbeck A/S, Sparrow Pharmaceuticals, Astellas Pharmaceuticals, and Acerand Therapeutics. O. Hamidi: Advisory board member for Neurocrine Biosciences, Corcept Therapeutics, Recordati Rare Diseases, Crinetics Pharmaceuticals, Inc, Camurus, Xeris Pharmaceuticals, Inc, Educational speaking engagement with Recordati Rare Diseases. I. Bancos: None. K. Saag: Recieved grants or contracts from Amgen, Arthrosi, Horizon, LG Pharma, Radius, and Olatec, Received consulting fees from Amgen, Anthrosi, Atom Bioscience, Horizon, LG Pharma, Angitia, and Gruenthal. H. Falhammar: None. U. Srirangalingam: Consulting fees from Crinetics Pharmaceuticals, Diurnal Ltd and H Lundbeck A/S. M. Calanchini: None. E. Jen: Full-time employee of Neurocrine Biosciences, Inc. V.H. Lin: Full-time employee of Neurocrine Biosciences, Inc. J. Sturgeon: Full-time employee of Neurocrine Biosciences, Inc. J.L. Chan: Full-time employee of Neurocrine Biosciences, Inc. Background: Crinecerfont, a corticotropin releasing factor type 1 receptor (CRF1) antagonist, is a first-in-class medication that is FDA-approved for adjunctive treatment to glucocorticoid (GC) replacement to control androgens in patients with classic congenital adrenal hyperplasia (CAH). In the Phase 3 CAHtalyst™ Adult study (NCT04490915), crinecerfont (100 mg BID) significantly reduced adrenal androgens, enabling substantial GC dose reductions from Day 1 baseline (BL) at the end of double-blind placebo-controlled (DBPC) treatment at Week 24, with a least-squares (LS) mean percent change of -27.3% vs. -10.3% for placebo (LS mean difference [LSMD] -17.0%, P<0.0001). At the end of open-label (OL) treatment at Month 12, mean percent decreases from BL in GC dose were -24.6% in participants who continued on crinecerfont (CFT/CFT) and -29.7% in those who switched from placebo (PBO/CFT). Objective: To evaluate clinical outcomes in adults with CAH who received up to 1 year of crinecerfont, in the context of substantial GC dose reductions. Methods: Outcomes related to excess adrenocorticotropic hormone (ACTH)/androgens (e.g., hirsutism in female participants) and GC exposure (e.g., body mass index [BMI], insulin resistance, hyperlipidemia) were analyzed at the end of DBPC treatment (Week 24) and the end of OL treatment (Month 12). DBPC outcomes with P-values are presented as LS mean changes with LSMD. Results: In female participants, mean hirsutism visual analog scale scores (out of 0 [no symptoms] to 100 [very severe symptoms]) were 40.6 (crinecerfont) and 37.4 (placebo) at BL. Changes from BL at end of DBPC (Week 24) and OL (Month 12) were: Week 24 (-9.8 for crinecerfont [n=58] vs -2.8 placebo [n=27], LSMD -7.0, P=0.1564); Month 12 (-11.5 CFT/CFT [n=56], -12.9 PBO/CFT [n=27]). Mean BMI at BL was 30.1 kg/m2 (crinecerfont) and 29.0 kg/m2 (placebo). Changes from BL were: at Week 24 (-0.4 vs. -0.02 for crinecerfont [n=118] vs. placebo [n=57], LSMD -0.40, P=0.1068); at Month 12 (-0.8 CFT/CFT [n=114], -0.4 PBO/CFT [n=56]). Mean homeostatic model assessment of insulin resistance values were high at BL (crinecerfont 3.2, placebo 3.0). Changes from BL were: at Week 24 (-0.6 vs. -0.4 for crinecerfont [n=61] vs placebo [n=29], LSMD -0.29, P=0.3454); at Month 12 (-0.5 CFT/CFT [n=107], -0.9 PBO/CFT [n=54]). Mean values for cholesterol (total, LDL, and HDL) and triglycerides were within normal range or near optimal at BL and remained stable. Conclusion: Adults with CAH who received up to 1 year of crinecerfont continued to show improvements in BMI and insulin resistance, as expected with lower GC doses. Moreover, despite substantial GC dose reductions, hirsutism in female participants improved with crinecerfont. Given the known adverse effects of ACTH/androgen excess and chronic supraphysiologic GC exposure, these results represent a promising therapeutic advancement in CAH. Presentation: Sunday, July 13, 2025
SUN-765 Retrospective Analysis of Pregnancy and Neonatal Outcomes in Hypoparathyroidism from the PARADIGHM Registry
Chung, Zinnia, Kamel, Loay, Shoback, Dolores , Khan, Aliya , Ali, Dalal S. , Kamel, Loay, Björnsdóttir, Sigríður , Clarke, B.L. , Gittoes, Neil , Hahner, Stefanie , Hofbauer, Lorenz C. , Houillier, Pascal , Ing, Steven , Levine, Michael A. , Mannstadt, Michael , Rejnmark, Lars , Brandi, Maria Luisa

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.713 Get It

Abstract Disclosure: D.S. Ali: None. Z. Chung: None. L. Kamel: None. S. Björnsdottir: Shire. B.L. Clarke: Shire, Takeda, Ascendis, Calcilytix. S. Hahner: None. L.C. Hofbauer: Amgen Inc, Ascendis, UCB, Ascendis, Amolyte. P. Houillier: None. S.W. Ing: Amgen Inc, Radius Health, Inc, Takeda, AscendAlexion, Amolyt, Ascendis, Calcilytix, Kyowa Kirin. M.A. Levine: Takeda, Amolyt, Calcilytix. M. Mannstadt: Takeda, Amolyt, Calcilytix. L. Rejnmark: Takeda, Amolyt, Ascendis, Calcilytix. D.M. Shoback: Amolyt, Ascendis, member of the advisory board (PARADIGHM). M. Brandi: Takeda, Eli Lilly & Company, Calcilytix, Kyowa Kirin, UCB, Abiogen, Alexion, Amolyt, Amorphical, Bruno Farmaceutici, CoGeDi, Echolight. A.A. Khan: Takeda, Amgen Inc, Alexion, Ascendis, Amolyt, Calcilytix. Background: Hypoparathyroidism (HypoPT) is a rare endocrine disorder that requires close evaluation and follow up during pregnancy to minimize maternal and fetal complications. The primary objectives of this study are to evaluate the use of rhPTH (1-84) during pregnancy by analyzing data from the PARADIGHM disease registry, and to compare maternal and neonatal outcomes among patients who continued PTH therapy during pregnancy versus those on conventional therapy (CT). Methods: We performed a retrospective analysis of data in the PARADIGHM registry. Maternal and neonatal outcomes in women treated with rhPTH (1-84) were compared to women who received CT. Results: We analyzed 39 pregnancies of 32 women. Of those, 4 women (6 pregnancies) used rhPTH (1-84) either before or during pregnancy and 28 women (33 pregnancies) continued CT during pregnancy. The mean (SD) maternal age at enrollment was 31.7 (5.6) years. Postsurgical HypoPT was the most common etiology (68.8%). The mean gestational age at delivery was 36 (2.4) weeks (PTH-treated) vs 38.3 (3.3) weeks (CT) (p=0.162). Preterm delivery rates were higher in the PTH-treated group (50% vs. 27%, p=0.591), but this was not statistically significant. Two women had pre-eclampsia, one in each group (PTH-treated and CT). In the PTH-treated group, one pregnancy resulted in a stillbirth, and one infant was born with congenital anomalies (16.7% each). Conclusions: The safety of rhPTH (1-84) use in pregnancy cannot be determined at this time. The PTH-treated group exhibited trends towards higher rates of preterm delivery, but the rates of stillbirth, and congenital anomalies were low and comparable in both groups of women. Larger studies are necessary to determine the optimal approach to manage women with HypoPT during pregnancy. Presentation: Sunday, July 13, 2025